Biotech-stock investing has one tough test for success - and it's about to get easier ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. Here's why these two high-yield ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...

BEAM-101 is an ex vivo genetic therapy delivered as part of an autologous haematopoietic stem cell transplant (HSCT) after a conditioning chemotherapy regimen to destroy the bone marrow and allow it ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Aamir Malik, Chief U.S. Commercial Officer ...

Sickle cell patient files lawsuit against Global Blood Therapeutics, a wholly owned subsidiary of Pfizer, alleging harm from medication. The lawsuit, filed on Hardiman's behalf by the law firm ...

Pfizer's COVID-19 products continue to generate significant cash flow that helps bolster the company's dividend. The big drugmaker has opportunities to monetize assets to raise additional cash ...